- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02718443
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
October 17, 2018 updated by: Vaximm GmbH
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
Study Overview
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Neurology Clinic and National Center for Tumor Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent, signed and dated
- Histologically diagnosed intracranial supratentorial malignant glioma (contrast-enhancing anaplastic astrocytoma WHO Grade III or glioblastoma WHO Grade IV).
- Male or female patients who must be post-menopausal for at least 2 years or surgically sterile.
- Age ≥18 years
- Evidence of tumor progression following at least one therapy regimen that must have contained radiation and chemotherapy with temozolamid, as measured by MRI
- Candidates for a tumor reoperation
- Neurosurgical intervention should be postponable for 30 days
- Laboratory results (clinical chemistry, hematology, urine, liver enzymes, creatinine) without clinically relevant abnormalities
- Patients must be able to undergo MRI
- No concomitant medication with dexamethasone at the time of vaccination
- No active infection at the time of vaccination
- Karnofsky performance status >70
- Appropriate hematologic parameters (for immunomonitoring): leukocytes ≥4.0 x 109 / L, lymphocytes ≥0.6 x 109 / L
- Tumor samples available for pathology review, central detection of T-cell responses in the peripheral blood and in the tumor tissue
- No medical or social conditions that may interfere with study outcome and follow-up
Exclusion Criteria:
- Treatment in any other clinical trial within 30 days before screening
- Known positive test results for Hepatitis B surface antigen , hepatitis C virus antibodies, human immunodeficiency virus antibodies -1/-2
- Any other condition or treatment that, in the opinion of the investigator, might interfere with the study or current drug or substance abuse
- Inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
- Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study
- Pregnancy or breast feeding
- Positive for anti-typhoid IgG/IgM antibodies according to the onsite test on Day 0
Cardiovascular disease defined as:
Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)
Arterial thromboembolic event within 6 months before randomization including:
- Myocardial infarction
- Unstable angina pectoris
- Cerebrovascular accident
- Transient ischemic attack
- Congestive heart failure New York Heart Association grade III to IV
- Serious ventricular arrhythmia requiring medication
- Clinically significant peripheral artery disease > grade 2b according to Fontaine
- Intracranial ischemic stroke within 6 months before randomization
- History of intracranial hemorrhage
- Hemoptysis within 6 months before randomization
- Esophageal varices
- Upper or lower gastrointestinal bleeding within 6 months before inclusion (Day 0)
- Significant traumatic injury or surgery within 4 weeks before randomization
- Non-healing wound, incomplete wound healing, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion
- Gastrointestinal fistula
- Thrombolysis therapy within 4 weeks before randomization
- Presence of any acute or chronic systemic infection
- Major surgical procedures, or open biopsy within 4 weeks before randomization
Chronic concurrent therapy within 2 weeks before and during the treatment period up to Day 35 with:
- Corticosteroids (except steroids for adrenal failure or emesis prophylaxis up to 4 mg daily dose) or immunosuppressive agents
- Antibiotics
- Bevacizumab
- Any cancer anti-angiogenic treatment
- Chemotherapy from screening until reoperation (Day 35)
- Known multi-drug resistant gram-negative germ
- History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications
- Women of childbearing potential
- Any condition which results in an undue risk for the patient during the study participation according to the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VXM01
VXM01 10E6 or 10E7 CFU
|
Oral immunotherapy targeting VEGFR2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability taking into account treatment-limiting toxicities (TLTs)
Time Frame: 12 months
|
AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken.
Frequency tables by System Organ Class and preferred term.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune Response by Enzyme Linked Immuno Spot (ELISpot)
Time Frame: 12 months
|
Patient-individual VEGFR-2 specific T cell responses will be determined by ELISpot using cryopreserved peripheral blood mononuclear cells
|
12 months
|
Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)
Time Frame: 12 months
|
Biomarkers including VEGF A and Collagen IV determined from periphaeral blood samples
|
12 months
|
Vascular normalization index (VNI) including tumor perfusion acc. to Sorensen 2009
Time Frame: 12 months
|
Determined by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) (ktrans), dynamic susceptibility contrast imaging (DSC), blood volume maps (cerebral blood volume [CBV] of smaller vessels) and collagen IV
|
12 months
|
Tumor immune cell infiltration by tumor tissue immunohistochemistry
Time Frame: 35 days
|
Tumor tissue immunohistochemistry staining including Evaluations of effector T cell infiltration, regulatory T-cells (Treg), myeloid derived suppressor cells (MDSC)
|
35 days
|
Tumor response or progression on MRI acc. to Response Assessment in Neuro-Oncology (RANO) criteria
Time Frame: 12 months
|
MRI comprising the National Brain Tumor Society /EORTC protocol for gliomas
|
12 months
|
Clinical Response including time to progression, progression free survival, overall survival
Time Frame: 12 months
|
12 months
|
|
Biodistribution and shedding of VXM01 bacteria
Time Frame: 10 days
|
Bacterial vector tissue biodistribution, persistence, and shedding of viable Ty21a bacteria (VXM01) determined by cultivation of stool samples
|
10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wolfgang Wick, MD, Neurology Clinic and National Center for Tumor Diseases
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Actual)
August 1, 2017
Study Completion (Actual)
July 1, 2018
Study Registration Dates
First Submitted
March 16, 2016
First Submitted That Met QC Criteria
March 18, 2016
First Posted (Estimate)
March 24, 2016
Study Record Updates
Last Update Posted (Actual)
October 19, 2018
Last Update Submitted That Met QC Criteria
October 17, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VXM01-02-DE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on VXM01
-
Vaximm GmbHCompletedColorectal CancerGermany
-
Vaximm GmbHCompletedStage IV Pancreatic CancerGermany
-
Vaximm GmbHPfizer; Merck KGaA, Darmstadt, GermanyActive, not recruiting